Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -22.36% is 85% above its 5-year average of -152.19%, near the high end of its 5-year range (-431.87%–59.55%).
As of the fiscal period ended Tuesday, June 30, 2026. 71.62% above its 12-month average of -78.78%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -22.36%.
RETURN ON EQUITY (ROE)
-22.36%
RETURN ON EQUITY (ROE) AVG TTM
-78.78%
RETURN ON EQUITY (ROE) AVG 3Y
-105.63%
RETURN ON EQUITY (ROE) AVG 5Y
-152.19%
RETURN ON EQUITY (ROE) AVG 10Y
-140.67%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+71.62%
CURRENT VS 3Y AVG
+78.83%
CURRENT VS 5Y AVG
+85.31%
CURRENT VS 10Y AVG
+84.10%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.15%
median of 712 covered companies
CURRENT VS SECTOR MEDIAN
+45.66%
vs the sector median at left
Avalo Therapeutics, Inc.
Market Cap
$701.23M
Return on Equity (ROE)
-22.36%
TTM Avg
-78.78%
3Y Avg
-105.63%
5Y Avg
-152.19%
Market Cap
$697.03M
Return on Equity (ROE)
-47.51%
TTM Avg
-32.80%
3Y Avg
-39.18%
5Y Avg
-31.37%
Market Cap
$689.08M
Return on Equity (ROE)
-44.63%
TTM Avg
-42.69%
3Y Avg
-38.09%
5Y Avg
-55.51%
Market Cap
$694.30M
Return on Equity (ROE)
-41.20%
TTM Avg
50554.28%
3Y Avg
25132.94%
5Y Avg
16622.35%
Market Cap
$710.62M
Return on Equity (ROE)
15.36%
TTM Avg
25.54%
3Y Avg
15.72%
5Y Avg
18.75%
Market Cap
$712.22M
Return on Equity (ROE)
-25.03%
TTM Avg
-10.49%
3Y Avg
-5.87%
5Y Avg
-23.97%
Market Cap
$677.86M
Return on Equity (ROE)
-55.36%
TTM Avg
-93.85%
3Y Avg
-76.06%
5Y Avg
-67.62%
Market Cap
$725.80M
Return on Equity (ROE)
N/A
TTM Avg
-222.26%
3Y Avg
276.12%
5Y Avg
157.82%
Market Cap
$728.31M
Return on Equity (ROE)
-70.19%
TTM Avg
-78.37%
3Y Avg
-123.45%
5Y Avg
-79.18%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | $701.23M | -22.36% | -78.78% | -105.63% | -152.19% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $697.03M | -47.51% | -32.80% | -39.18% | -31.37% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $689.08M | -44.63% | -42.69% | -38.09% | -55.51% |
| Anteris Technologies Global Corp. (AVR)vs › | $694.30M | -41.20% | 50554.28% | 25132.94% | 16622.35% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $710.62M | 15.36% | 25.54% | 15.72% | 18.75% |
| Cytek Biosciences, Inc. (CTKB)vs › | $712.22M | -25.03% | -10.49% | -5.87% | -23.97% |
| Solid Biosciences Inc. (SLDB)vs › | $677.86M | -55.36% | -93.85% | -76.06% | -67.62% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $725.80M | N/A | -222.26% | 276.12% | 157.82% |
| Candel Therapeutics, Inc. (CADL)vs › | $728.31M | -70.19% | -78.37% | -123.45% | -79.18% |
| Helus Pharma Inc. (HELP)vs › | $672.22M | -75.79% | -55.51% | -59.06% | -60.41% |
ROE
-22.4%
ROA
-20.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -22.36% |
| 2026-03-31 | -124.03% |
| 2025-12-31 | -94.23% |
| 2025-09-30 | -109.10% |
| 2025-06-30 | -44.19% |
| 2025-03-31 | 59.55% |
| 2024-12-31 | -26.41% |
| 2024-09-30 | -37.76% |
| 2023-12-31 | -431.87% |
| 2023-09-30 | -225.85% |
| 2021-12-31 | -365.55% |
| 2021-09-30 | -200.51% |
| 2021-06-30 | -356.16% |
| 2021-03-31 | -220.37% |
| 2020-12-31 | -258.53% |
| 2020-09-30 | -119.88% |
| 2020-06-30 | -72.75% |
| 2020-03-31 | -116.21% |
| 2019-12-31 | -76.55% |
| 2019-09-30 | -127.61% |
| 2019-06-30 | -247.73% |
| 2019-03-31 | -188.68% |
| 2018-12-31 | -191.57% |
| 2018-09-30 | -192.67% |
| 2018-06-30 | 29.86% |
| 2018-03-31 | 40.47% |
| 2017-12-31 | 42.61% |
| 2017-09-30 | 60.23% |
| 2017-06-30 | -368.90% |
| 2016-06-30 | -233.41% |
| 2016-03-31 | -139.53% |
| 2015-12-31 | -80.17% |
